Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide
Authors' conclusion
Tirzepatide, semaglutide, and liraglutide reduced bodyweight and improved in selected metabolic risk markers over 12 months without increasing the risk for hypoglycaemia or DKA. Weight loss appeared less compared with patients without diabetes. Tirzepatide, semaglutide and liraglutide modestly improved glycaemic control in adults with T1D and obesity. These findings support the potential adjunctive role of GLP-1 receptor agonists in people with obesity and T1D and underscore the need for further validation through randomized controlled trials.
Study context
- Population
- People with BMI ≥27 kg/m² and T1D (obesity and T1D; female = 54.8%)
- Participants
- 250 people
- Exposure
- Tirzepatide vs semaglutide vs liraglutide vs usual care
- Tirzepatiden = 35
- Semaglutiden = 36
- Liraglutiden = 97
- Usual caren = 82reference
- Outcome
- Body weight change
- Follow-up
- 12 months
Main finding
As reported in the abstract
- Tirzepatide weight loss, p
- P < 0.001
- Semaglutide weight loss, p
- P < 0.001
- Liraglutide weight loss, p
- P < 0.001
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Tirzepatide | Semaglutide | Liraglutide |
|---|---|---|---|
| HbA1c reduction · 12 months | 0.65% | 0.33% | 0.23% |
| p | p = 0.004 | p = 0.034 | p = 0.017 |
HbA1c reduction · 12 months
- No change in HbA1c with usual care
LDL-C · 12 months
- LDL-C reduced by semaglutide
- P = 0.05
- LDL-C reduced by liraglutide
- P = 0.02
Urine albumin-to-creatinine ratio · 12 months
- Lowered by liraglutide
- P = 0.007
Safety
Severe hypoglycaemia or diabetic ketoacidosis (DKA) events · 12 months
- No severe hypoglycaemia or DKA events were reported in any group
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →